E-MAIL UPDATES

Click here to join
our Electronic Communications.

Whats new

Presentations.

Presentations

February 19th 2020

German Cancer Congress presentation of TACTI-002 interim data

January 10th 2020

Corporate Presentation

December 12th 2019

San Antonio Breast Cancer Symposium - poster presentation of AIPAC (Active Immunotherapy PAClitaxel)

November 8th 2019

SITC 2019 - poster presentation of TACTI-002 interim data

November 1st 2019

2019 AGM CEO Presentation

October 15th 2019

World Immunotherapy Congress 2019 presentation of TACTI-mel melanoma trial data

September 30th 2019

Corporate Presentation

June 26th 2019

Immutep KOL Event Presentation: A Novel IO Therapy (eftilagimodalpha) in Metastatic Breast Cancer and other settings

June 1st 2019

INSIGHT Trial - Poster - ASCO 2019

June 1st 2019

TACTI-002 (Two ACTive Immunotherapeutics) - Poster - ASCO 2019

May 21st 2019

Corporate Presentation

May 17th 2019

Advanced Therapies and Regenerative Medicine London

April 2nd 2019

Immutep to Present Eftilagimod Alpha Clinical Development Update and New Data from Ongoing Melanoma Study

Listen to the related webcast:  Update on Eftilagimod Alpha (IMP321)

March 25th 2019

Immutep to Present IMP761 Preclinical Results in Global Webcast

Listen to the related webcast: Immutep IMP761 Preclinical Results in Autoimmune Disease

March 7th 2019

Congress of European Crohn’s and Colitis Organisation (ECCO) Conference Presentation

March 5th 2019

World Immunotherapy Congress USA 2019 Presentation

February 24th 2019

Immutep Presentation to Emergence Conference

January 7th 2019

Corporate Presentation

November 27th 2018

4th Annual ICI Europe Summit Presentation

November 9th 2018

Oral Presentation - TACTI-mel - 33rd Annual Meeting SITC 2018, Washington, D.C., USA

November 9th 2018

Poster Presentation - TACTI-mel - 33rd Annual Meeting SITC 2018, Washington, D.C., USA

Results from a Phase I dose escalation trial (TACTImel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma

November 9th 2018

Poster Presentation - TACTI-002 - 33rd Annual Meeting SITC 2018, Washington, D.C., USA

A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractory NSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination with Pembrolizumab (TACTI-002)

November 9th 2018

Corporate Investor Presentation

October 30th 2018

Presentation at World Immunotherapy Congress 2018, Basel, Switzerland

Two ACTive immunotherapies in melanoma (TACTI-mel):
results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab

October 30th 2018

Ausbiotech Presentation

October 29th 2018

Corporate Presentation

October 24th 2018

TACTI-mel Trial - Society for Melanoma Research Poster

October 2nd 2018

Presentation at Ladenburg Thalmann 2018 Healthcare Conference

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

September 7th 2018

Newsmakers Immutep Corporate Presentation

Listen to the webcast “Immutep Newsmakers Presentation”

Download "Newsmaker Immutep Corporate Presentation"

August 29th 2018

Corporate Investor Presentation

June 4th 2018

INSIGHT Trial - ASCO Poster

June 3rd 2018

AIPAC Trial In Progress - ASCO Poster

June 3rd 2018

AIPAC Safety Run-In - ASCO Poster

May 30th 2018

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update (Webcast)

May 30th 2018

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update

May 25th 2018

3rd Annual Advances in Immuno-Oncology Congress Presentation

May 17th 2018

Presentation at 13th Annual Advanced Therapy and Regenerative Medicine Congress 2018, London

LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?

May 17th 2018

Corporate Presentation

March 22nd 2018

Presentation at 3th Annual Immuno-Oncology Summit Europe, London

LAG-3: Identification & Validation Of Next Generation Checkpoint Pathway

January 5th 2018

Corporate Presentation

November 1st 2017

SITC 2017 Poster Presentation

November 1st 2017

Presentation at ICI Europe Summit

Combination Strategies for LAG-3Ig (IMP321) With Either Chemotherapy or Anti-PD-1 Therapy

October 1st 2017

Presentation at the World Immunotherapy Congress 2017

August 1st 2017

Corporate Presentation

June 1st 2017

ASCO poster presentation

March 1st 2017

Presentation at the Precision Breast Cancer Conference, Boston

March 1st 2017

Presentation at ICI conference

February 1st 2017

Presentation at the International Molecular Medicine Tri-Conference

November 11th 2016

SITC Presentation

November 4th 2016

ESMO poster presentation about TACTI-mel trial

October 24th 2016

Corporate Presentation

May 1st 2016

Canary Stocks to Watch Roadshow, Sydney, Australia

April 4th 2016

ESMO poster presentation about AIPAC trial

April 1st 2016

Immune Checkpoint Modulation & Combination Therapies

January 1st 2016

Corporate Presentation

November 25th 2015

Annual General Meeting - CEO Presentation

September 29th 2015

Corporate Presentation

August 9th 2015

Rodman & Renshaw Global Investment Conference

August 1st 2015

CEO Presentation Extraordinary General Meeting

May 1st 2015

Capital Raising Presentation

May 1st 2015

Corporate Presentation

January 11th 2015

Presentation of Frédéric Triebel